IGL is working to ensure that laws, rules and practices in the Danish Health Care and Life science service continue to address opportunities to offer Danish patients safe, effective and affordable generic and biosimilar medicines. IGL wishes to contribute to the public debate on medicine and medical expenses, just as the association sees it as its task to influence politicians, authorities and operators in the Danish Health Care and Life Science service.

IGL is working for an improved access to medicines for patients and for a reduction of the cost of medicine for consumers and society through the advancement of the sale of generic and biosimilar medicines in Denmark.